Beyond the Drop Bottle: The Rise of Interventional Glaucoma
For decades, the gold standard for managing elevated intraocular pressure (IOP) was a “drops-first” approach. However, a significant paradigm shift is occurring. We are moving toward an interventional model that prioritizes stable IOP control whereas minimizing the daily treatment burden on the patient.
This evolution, termed “interventional glaucoma,” focuses on achieving pressure stability through targeted procedures rather than relying solely on chronic topical therapy. By identifying the “interventional window” earlier, practitioners can prevent irreversible damage to the eye’s surface and improve long-term surgical outcomes.
Breaking the “Preservative Cycle” to Save the Ocular Surface
The hidden cost of long-term topical therapy is often found in the preservatives, specifically benzalkonium chloride (BAK). This quaternary ammonium compound acts as a detergent, disrupting the tear film lipid layer and triggering evaporative dry eye.
Beyond simple dryness, BAK induces a pro-inflammatory cascade, upregulating cytokines like IL-6 and IL-8. This leads to goblet cell loss and squamous metaplasia of the ocular surface epithelium. The consequences are not just about comfort; a chronically inflamed conjunctiva can lead to higher failure rates in future subconjunctival filtration surgeries due to enhanced fibrotic responses.
By utilizing Microinvasive Glaucoma Surgery (MIGS) or selective laser trabeculoplasty, clinicians can reclaim the ocular surface from chemical assault, ensuring a healthier environment for both the patient and future surgical interventions.
The Impact on Refractive Accuracy
A compromised ocular surface directly interferes with the success of cataract surgery. BAK-induced keratopathy can make accurate biometry and keratometry nearly impossible. An unstable tear film creates irregular astigmatism, which often leads to IOL power calculation errors and suboptimal refractive outcomes.
Precision IOL Selection: Why EDOF is Replacing Trifocals
Selecting the right intraocular lens (IOL) for a patient with glaucoma requires a deep understanding of progressive neuropathy. While trifocal IOLs are popular for achieving “spectacle-free” vision, they are rarely appropriate for glaucoma patients.
The primary issue is contrast sensitivity. Trifocal lenses split incoming light into multiple foci, which reduces contrast. Since glaucoma erodes contrast sensitivity—often before affecting Snellen acuity—layering a trifocal lens over a compromised optic nerve can significantly degrade visual quality, especially in low-light conditions.
The EDOF Advantage
Extended Depth of Focus (EDOF) IOLs offer a safer alternative for patients with mild-to-moderate, stable glaucoma. These lenses provide a continuous range of vision with a much lower impact on contrast sensitivity than diffractive multifocals.
- Preserved Contrast: EDOF lenses maintain contrast sensitivity closer to monofocal levels.
- Visual Field Integrity: Unlike trifocals, EDOF lenses present no difference in visual field sensitivity on standard automated perimetry.
- Reduced Dysphotopsias: Refractive designs, such as the Tecnis PureSee, minimize the glare and halos that can be particularly disruptive for glaucoma patients.
Comparing Modern EDOF Options
Current options in the Australian market include non-diffractive EDOF (Vivity-type) which uses wavefront-shaping technology, and next-generation refractive EDOF (TECNIS PureSee) which aims for visual side effects comparable to monofocal IOLs. For those with moderate glaucoma, enhanced monofocal IOLs (like Eyhance or RayOne EMV) provide a mild extension of depth of focus with minimal compromise to visual quality.
The Evolution of MIGS: From Combined to Standalone Care
MIGS is no longer viewed as a last resort or a procedure strictly tied to cataract surgery. The “treatment pyramid” has flattened, making minimally invasive options a foundational pillar of care.
A key advancement is the move toward multi-stent systems. For example, the iStent infinite system utilizes three heparin-coated titanium stents placed across approximately 240° (or 8 clock hours) of the canal, addressing the natural segmental flow of the eye’s drainage system.
Crucially, these systems now carry standalone indications in Australia. This means patients struggling with medication intolerance or IOP fluctuations can receive surgical solutions without waiting for the development of cataracts.
Real-World Application: Case Studies
The Refractive Seeker: A 55-year-old software architect with mild glaucoma suffered from debilitating dry eye due to latanoprost. By undergoing bilateral standalone iStent infinite procedures, the patient achieved an IOP of 15 mmHg on zero medications. This not only restored ocular surface comfort but established stable biometry for future EDOF IOL planning.
The Steroid Responder: A 62-year-old patient with diabetic macular oedema experienced severe IOP spikes (up to 34 mmHg) due to necessary dexamethasone implants. The implantation of an iStent infinite trabecular micro-bypass stabilized the IOP at 14-16 mmHg, allowing the patient to continue vital steroid treatment without risking optic nerve damage.
The Multi-Drop Patient: A 68-year-old on three topical medications suffered from Grade 3 punctate keratitis and fluctuating vision. A combined approach—cataract surgery with iStent infinite and an EDOF IOL—resulted in an IOP of 13 mmHg on zero medications and a complete resolution of ocular surface disease.
Identifying the Interventional Window
Early referral is critical. Practitioners should look for specific clinical signals that suggest a patient has entered the “interventional window”:
- The “Fluctuator”: Patients with significant visit-to-visit IOP variations, often signaling poor adherence.
- Ocular Surface Distress: Presence of follicular conjunctivitis or reduced tear break-up time.
- The Refractive Seeker: Patients desiring premium EDOF outcomes who need surface optimization first.
- The Steroid Responder: Patients experiencing IOP spikes secondary to necessary steroid therapy.
Frequently Asked Questions
What is the main risk of using trifocal IOLs in glaucoma patients?
Trifocal IOLs split light into multiple foci, which reduces contrast sensitivity. Due to the fact that glaucoma already erodes contrast, these lenses can significantly degrade visual quality.
Can MIGS be performed without cataract surgery?
Yes. Certain systems, such as the iStent infinite, have standalone indications in Australia, allowing for IOP control and medication reduction in phakic patients.
How does BAK affect future glaucoma surgeries?
Benzalkonium chloride (BAK) causes chronic subclinical inflammation and increases conjunctival fibroblast activation, which can accelerate post-operative scarring and reduce the success of trabeculectomies.
Why are EDOF lenses preferred over multifocals for glaucoma?
EDOF lenses preserve contrast sensitivity and do not negatively impact visual field sensitivity on standard automated perimetry, making them safer for a compromised optic nerve.
Want to stay updated on the latest in interventional glaucoma and refractive surgery? Explore more of our expert guides on glaucoma management or subscribe to our newsletter for the latest industry insights.
